Floatz logo

241 assets in Parkinson Disease

Therapeutic assets addressing Parkinson Disease, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Gamma-Glutamylcysteine
Parkinson Disease
Pravat MandalP1CC (43)
Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors
Parkinson Disease
University of California, San DiegoP1CC (43)
mrx0005
Parkinson Disease
4D pharma plcP1CC (43)
mrx0029
Parkinson Disease
4D pharma plcP1CC (43)
Ux-Da001
Parkinson Disease
Shanghai UniXell Biotechnology Co., LtdP1CC (43)
Vgn-R09B
Parkinson Disease
Shanghai Vitalgen BioPharma Co., Ltd.P1/2CC (43)
Allogeneic Dopaminergic Neural Precursor Cell
Parkinson Disease
Nuwacell Biotechnologies Co., Ltd.P1CC (42)
Dipraglurant
Parkinson Disease
Addex Pharma S.A.P2/3CC (42)
Dsp-9632P
Parkinson Disease
Sumitomo Pharma Co., Ltd.P1CC (42)
[18F]MC225
Parkinson Disease
University Medical Center GroningenP1/2CC (41)
aav2-haadc
Parkinson Disease
Krzysztof BankiewiczP1CC (41)
Febuxostat
Parkinson Disease
Fujita Health UniversityP1CC (41)
ly3884961
Parkinson Disease
Prevail TherapeuticsP1/2CC (41)
mtx325
Parkinson Disease
Mission TherapeuticsP1CC (41)
sst001
Parkinson Disease
Synusight Biotech (Shanghai) Co., Ltd.P1CC (41)
Vent-02
Parkinson Disease
Ventus Therapeutics U.S., Inc.P1/2CC (41)
vt-5006
Parkinson Disease
Vertero TherapeuticsP1CC (41)
[18f]p17-059
Parkinson Disease
Five Eleven Pharma, Inc.P1CC (40)
[18f]ucb-2897
Parkinson Disease
InvicroP1CC (40)
Allopregnan-3.Alpha.-Ol-20-One
Parkinson Disease
Roberta BrintonP1CC (40)
Flortaucipir
Parkinson Disease
Mayo ClinicP1CC (40)
Neurotop
Parkinson Disease
Cerevel Therapeutics, LLCP1CC (40)
pdm608
Parkinson Disease
Calibr, a division of Scripps ResearchP1CC (40)
Selnoflast
Parkinson Disease
Hoffmann-La RocheP1CC (40)
Spartalizumab
Parkinson Disease
Ruijin HospitalP1CC (40)
TRN501
Parkinson Disease
SNLD, Ltd.P1CC (40)
11C-MC1
Parkinson Disease
National Institute of Mental Health (NIMH)P1C (39)
[11c]modag-005
Parkinson Disease
MODAG GmbHEarly P1C (39)
Autologous Induced Neural Stem Cell-Derived Da Precursor Cells
Parkinson Disease
Xuanwu Hospital, BeijingP1C (39)
Dna (Recombinant Human Adenovirus 5 .Delta.E1B-19K Oncolytic Vector Gm101 Human Modified Telomerase Promoter Plus Human Relaxin 1 Precursor-Specifying)
Parkinson Disease
Genemagic Biosciences Co., LtdEarly P1C (39)
Florbetaben
Parkinson Disease
National Institute of Mental Health (NIMH)P1C (39)
jx2105
Parkinson Disease
Zhejiang Jingxin Pharmaceutical Co., Ltd.P1C (39)
ly3962681
Parkinson Disease
Prevail TherapeuticsP1C (39)
PS13
Parkinson Disease
National Institute of Mental Health (NIMH)P1C (39)
Rgl-193（High-Dose）
Parkinson Disease
Second Affiliated Hospital of Soochow UniversityEarly P1C (39)
Rgl-193　(Low-Dose)
Parkinson Disease
Second Affiliated Hospital of Soochow UniversityEarly P1C (39)
[18F]ACI-15916
Parkinson Disease
AC Immune SAEarly P1C (38)
[18F]MK-0947
Parkinson Disease
InvicroEarly P1C (38)
Alloex
Parkinson Disease
The Foundation for Orthopaedics and Regenerative MedicineP1C (37)
ams2434
Parkinson Disease
University of ArkansasP1C (37)
Anpd001
Parkinson Disease
Aspen NeuroscienceP1C (37)
Autologous Midbrain Dopamine Neurons
Parkinson Disease
Penelope J. Hallett, Ph.D.P1C (37)
Bms-9894923
Parkinson Disease
Allyx TherapeuticsP1C (37)
Clozapine
Parkinson Disease
Ruijin HospitalEarly P1C (37)
hl-400
Parkinson Disease
Highlightll Pharmaceutical (USA) LLCP1C (37)
Huc-Msc-Sev-001 Nasal Drops
Parkinson Disease
Xuanwu Hospital, BeijingP1C (37)
Human Fgf-1
Parkinson Disease
Zhittya Genesis Medicine, Inc.P1C (37)
ips101a
Parkinson Disease
Innopeutics CorporationP1C (37)
Lbt-3627
Parkinson Disease
Longevity Biotech Australia Pty Ltd (subsidiary)P1C (37)
ly4006896
Parkinson Disease
Eli Lilly and CompanyP1C (37)
Showing 151 to 200 of 241 assets
PreviousPage 4 of 5Next